NICaS provides a real-time, continuously accurate1,2,3 and highly reproducible4 hemodynamic status including: stroke volume, cardiac output, total peripheral resistance, cardiac power index and total body water.
NICaS can help you:
Assess inclusion criteria
Obtain real-time dose titration information
Monitor cardiac safety in both cardiovascular and non-cardiovascular trials
Evaluate drug efficacy and safety
Support single or multi-site clinical trials
Document desired and adverse effects of candidate compounds
Reduce total trial time by facilitating patient recruitment
Decrease time-to-market of successful compounds
NICaS unique technology:
Allows easy application with only two sensors
Secure the data transfer to the core lab
Accurately assess the smallest hemodynamic changes
Paredes OL, Shite J, Shinke T, et al. Impedance cardiography for cardiac output estimation: reliability of wrist-to-ankle electrode configuration. Circ J. 2006;70(9):1164-1168. doi:10.1253/circj.70.1164
Cotter G, Schachner A, Sasson L, Dekel H, Moshkovitz Y. Impedance cardiography revisited. Physiol Meas. 2006;27(9):817-827. doi:10.1088/0967-3334/27/9/005
Cotter G, Moshkovitz Y, Kaluski E, et al. Accurate, noninvasive continuous monitoring of cardiac output by whole-body electrical bioimpedance. Chest. 2004;125(4):1431-1440. doi:10.1378/chest.125.4.1431
Tita C, Gilbert EM, Van Bakel AB, et al. A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2017;19(10):1321-1332. doi:10.1002/ejhf.897